Stacey Brett R, Swift Jon N
Department of Anesthesiology & Peri-Operative Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode OP-26, Portland, OR 97239, USA.
Curr Pain Headache Rep. 2006 Jun;10(3):179-84. doi: 10.1007/s11916-006-0043-x.
Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein-bound, and has minimal drug-drug interactions. It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily. Seven published prospective, randomized clinical trials in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) demonstrate pain relief, decreased sleep interference, and improvements in several secondary outcome measures. The 50% responder rates for PHN and DPN compare favorably with other first-line agents for neuropathic pain. Pregabalin is well tolerated in most patients with infrequent severe adverse effects. Pregabalin is an important addition to the treatment armamentarium for neuropathic pain.
普瑞巴林是电压门控钙通道α-2-δ亚基的配体，具有抗惊厥、镇痛和抗焦虑特性。它在胃肠道的吸收具有可预测性，既不被代谢也不与蛋白质结合，且药物相互作用极小。每日剂量在150至600毫克范围内，分两到三次服用有效。七项已发表的关于带状疱疹后神经痛（PHN）和疼痛性糖尿病周围神经病变（DPN）的前瞻性随机临床试验表明，该药可缓解疼痛、减少睡眠干扰，并改善多项次要结局指标。PHN和DPN的50%缓解率优于其他用于神经性疼痛的一线药物。大多数患者对普瑞巴林耐受性良好，严重不良反应少见。普瑞巴林是神经性疼痛治疗药物库中的重要补充药物。
